<DOC>
	<DOCNO>NCT00444704</DOCNO>
	<brief_summary>The primary purpose study assess safety tolerability ascend single oral dos PRA-027 healthy Japanese female . The secondary purpose provide initial pharmacokinetic pharmacodynamic profile PRA-027 healthy Japanese female subject .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics Pharmacodynamics PRA-027 Administered Healthy Japanese Females</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Women nonchildbearing potential age 20 64 year . Must negative pregnancy test result within 48 hour administration test article . Women surgically sterile must provide documentation procedure operative report ultrasound scan . 2 . Body mass index ( BMI ) range 17.6 26.4 kg/m2 body weight must least 45 kg . 3 . Healthy determine investigator basis screen evaluation . EXCLUSION CRITERIA 1 . Any significant cardiovascular , hepatic , renal , respiratory , gynecologic gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . 2 . Any history drug abuse admit alcohol abuse history alcohol use may interfere subject 's ability comply protocol requirement . 3 . Use investigational drug within 90 day study day 1 , use prescription drug within 30 day study day 1 , consumption caffeinecontaining product ( eg , coffee , tea , chocolate , cola ) alcoholic beverage within 48 hour study day 1 , consumption grapefruit grapefruitcontaining product within 72 hour study day 1 , use overthecounter drug , include herbal supplement ( except occasional use vitamin â‰¤100 % recommended daily allowance ) , within 14 day study day 1 , donation blood within 90 day study day 1 .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>